Traders purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading on Friday. $331.19 million flowed into the stock on the tick-up and $102.03 million flowed out of the stock on the tick-down, for a money net flow of $229.16 million into the stock. Of all stocks tracked, Johnson & Johnson had the 3rd highest net in-flow for the day. Johnson & Johnson traded down ($0.18) for the day and closed at $123.00

Several brokerages have recently commented on JNJ. Societe Generale began coverage on Johnson & Johnson in a research note on Wednesday, April 6th. They issued a “hold” rating and a $113.00 price target on the stock. BTIG Research lowered Johnson & Johnson from a “buy” rating to a “neutral” rating in a research note on Thursday, May 12th. Piper Jaffray Cos. boosted their price objective on Johnson & Johnson from $105.00 to $106.00 and gave the company a “neutral” rating in a report on Wednesday, April 20th. Morgan Stanley reiterated a “hold” rating on shares of Johnson & Johnson in a report on Thursday, May 19th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $112.77.

The firm has a market capitalization of $338.33 billion and a price-to-earnings ratio of 22.42. The stock has a 50-day moving average price of $118.11 and a 200 day moving average price of $109.60.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 19th. The company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.65 by $0.03. During the same period in the previous year, the firm posted $1.56 earnings per share. The business had revenue of $17.50 billion for the quarter, compared to analysts’ expectations of $17.50 billion. The firm’s revenue was up .6% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post $6.61 earnings per share for the current year.

In other news, CAO Ronald A. Kapusta sold 3,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $115.79, for a total transaction of $347,370.00. Following the sale, the chief accounting officer now directly owns 28,725 shares of the company’s stock, valued at $3,326,067.75. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Ronald A. Kapusta sold 3,957 shares of Johnson & Johnson stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $114.77, for a total value of $454,144.89. Following the sale, the chief accounting officer now directly owns 29,682 shares in the company, valued at $3,406,603.14. The disclosure for this sale can be found here.

Other hedge funds have recently made changes to their positions in the company. Central Securities Corp raised its stake in shares of Johnson & Johnson by 40.0% in the fourth quarter. Central Securities Corp now owns 70,000 shares of the company’s stock valued at $7,190,000 after buying an additional 20,000 shares in the last quarter. Morningstar Investment Services LLC raised its stake in shares of Johnson & Johnson by 7.4% in the fourth quarter. Morningstar Investment Services LLC now owns 398,382 shares of the company’s stock valued at $40,922,000 after buying an additional 27,315 shares in the last quarter. Ashburton Jersey Ltd purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $18,234,000. Foresters Investment Management Company Inc. raised its stake in shares of Johnson & Johnson by 1.1% in the fourth quarter. Foresters Investment Management Company Inc. now owns 554,250 shares of the company’s stock valued at $56,933,000 after buying an additional 5,900 shares in the last quarter. Finally, Home Federal Bank of Tennessee purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $1,887,000.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.